Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease	Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis	Active, not recruiting	Not stated	2026-05-08		NCT07123350

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Takeda Pharmaceuticals U.S.A., Inc.	3
Vanderbilt University Medical Center	299

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Vanderbilt University Medical Center	Nashville	United States	1

Clinical trials